CAM Group Holding A S cut its position in Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 48.3% during the second quarter, Holdings Channel reports. The fund owned 123,000 shares of the specialty pharmaceutical company’s stock after selling 115,000 shares during the period. CAM Group Holding A S’s holdings in Supernus Pharmaceuticals were worth $2,506,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the company. BlackRock Fund Advisors boosted its stake in shares of Supernus Pharmaceuticals by 1.1% in the first quarter. BlackRock Fund Advisors now owns 2,826,989 shares of the specialty pharmaceutical company’s stock worth $43,112,000 after buying an additional 31,238 shares during the last quarter. Rice Hall James & Associates LLC raised its position in Supernus Pharmaceuticals by 1.3% in the second quarter. Rice Hall James & Associates LLC now owns 543,606 shares of the specialty pharmaceutical company’s stock worth $11,073,000 after buying an additional 7,161 shares during the period. Alps Advisors Inc. raised its position in Supernus Pharmaceuticals by 26.2% in the second quarter. Alps Advisors Inc. now owns 69,426 shares of the specialty pharmaceutical company’s stock worth $1,414,000 after buying an additional 14,407 shares during the period. Nicholas Investment Partners LP purchased a new position in Supernus Pharmaceuticals during the first quarter worth approximately $1,990,000. Finally, Granahan Investment Management Inc. MA purchased a new position in Supernus Pharmaceuticals during the first quarter worth approximately $5,945,000. Hedge funds and other institutional investors own 94.62% of the company’s stock.
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) traded up 0.44% during mid-day trading on Wednesday, reaching $20.71. 463,575 shares of the company’s stock traded hands. Supernus Pharmaceuticals Inc. has a one year low of $9.51 and a one year high of $26.84. The firm’s 50-day moving average price is $23.49 and its 200 day moving average price is $20.43. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of 42.27 and a beta of 1.73.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.05. The business had revenue of $50.40 million for the quarter, compared to analysts’ expectations of $49.67 million. Supernus Pharmaceuticals had a net margin of 14.94% and a return on equity of 20.99%. The company’s revenue was up 43.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.03 EPS. On average, equities analysts forecast that Supernus Pharmaceuticals Inc. will post $0.68 EPS for the current year.
Several brokerages recently issued reports on SUPN. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Jefferies Group set a $28.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 13th. Northland Securities lowered shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price for the company. in a research report on Monday, July 18th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $25.25.
In other news, CFO Gregory S. Patrick sold 2,000 shares of the firm’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the sale, the chief financial officer now directly owns 3,616 shares in the company, valued at approximately $90,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.10% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.